Abiraterone and Increased Survival in Metastatic Prostate Cancer
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index; 17 of the 40 sources its claims cite were checked for support.
Abstract
BACKGROUND: Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy. METHODS: We randomly assigned, in a 2:1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate. RESULTS: After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo-prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001). Data were unblinded at the interim analysis, since these results exceeded the preplanned criteria for study termination. All secondary end points, including time to PSA progression (10.2 vs. 6.6 months; P<0.001), progression-free survival (5.6 months vs. 3.6 months; P<0.001), and PSA response rate (29% vs. 6%, P<0.001), favored the treatment group. Mineralocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo-prednisone group. CONCLUSIONS: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 7 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A unique molecular alteration described in castration-resistant prostate cancer is the up-regulation of androgen biosynthesis enzymes, leading to an increase in intratumoral androgen concentrations, which can exceed the levels measured in the blood.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [7] matched to “Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance” (2004) source
- Partly supportedcites [8] matched to “Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer” (2006) sourceExperimental — accuracy not yet measured
The Abstract and Discussion (page numbers unavailable) report increased expression of androgen-metabolism genes in androgen-independent prostate cancer and propose enhanced intracellular conversion of adrenal androgens as a mechanism for substantial tissue androgen levels. The paper does not state that intratumoral androgen concentrations exceed blood levels; its tissue comparison is with normal or nonneoplastic prostate. (LLM, conf=0.88)
- Partly supportedcites [9] matched to “Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth” (2008) sourceExperimental — accuracy not yet measured
The Results report up-regulated transcripts for androgen-biosynthesis enzymes in castration-resistant metastases and say tumor testosterone concentrations exceeded equivalent concentrations in the patients’ serum. But the Discussion says the processes sustaining intratumoral androgens have yet to be determined and proposes enzyme modulation as a possible mechanism; it does not establish that the up-regulation caused the higher concentrations. No page number is available in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Treatment with abiraterone acetate did not appear to increase the risk of metabolic changes or symptoms associated with chronic androgen deprivation.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Could not verifycites [42] matched to “Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer” (2010) sourceExperimental — accuracy not yet measured
The Methods passage describes GnRH agonists, orchiectomy, and oral antiandrogens, but does not identify abiraterone acetate as a treatment studied. The Results and Discussion address diabetes and cardiovascular outcomes for those treatments, not metabolic changes or symptoms during abiraterone treatment. Searches for “abiraterone acetate” and the claimed metabolic changes and symptoms found no passage addressing that specific claim. (LLM, conf=0.77)
- Could not verifycites [43] matched to “Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology” (2010) sourceExperimental — accuracy not yet measured
The 'Adverse Effects of ADT' section describes metabolic changes associated with androgen-deprivation therapy generally, but does not assess abiraterone acetate. Searches for 'abiraterone acetate' and 'symptoms associated with chronic androgen deprivation' found no passage addressing whether abiraterone increases those risks. (LLM, conf=0.76)
- Not checked yetcites [44] matched to “Management of Complications of Prostate Cancer Treatment” (2008) source
- Not checked yetcites [45] matched to “Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer” (2004) source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These results show that continued androgen-receptor signaling contributes to disease progression”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Not checked yetcites [2] matched to “Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis” (2005) source
- Supportedcites [10] matched to “Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?” (2009) source
The Abstract of the Attard et al. (2009) Cancer Cell preview states that 'clinical data from abiraterone acetate and MDV-3100 confirm continued androgen receptor (AR) addiction in a significant proportion of castration-resistant prostate cancers,' and the Main Text adds that 'the growth of the majority of cancer cells in many patients with cancers recurring after castration remains dependent on the AR signaling axis,' with nuclear AR expression persisting in metastases and AR transcriptional activity described as 'required for prostate cancer progression' (Hormone-Driven Oncogenesis). The conclusion reiterates that a significant proportion of CRPC finds AR signaling 'a hard habit to break.' This covers the claim's substance — persistent AR signaling contributing to progression in metastatic CRPC — though the source phrases it as addiction/persistence in a significant proportion rather than in all patients. (LLM, conf=0.88)
- Not checked yetcites [31] matched to “Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling” (2011) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In phase 1–2 trials, treatment with abiraterone acetate, either as a single agent or in combination with low-dose glucocorticoids such as prednisone, resulted in significant antitumor activity among both patients with progressing castration-resistant prostate cancer who had not received chemotherapy and those who had received chemotherapy.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
The Abstract Patients and Methods (p.1) and Introduction state this phase I/II trial enrolled castrate, chemotherapy-naive CRPC patients only, and the PATIENTS AND METHODS > Patients section explicitly excludes 'Patients who had previously received cytotoxic chemotherapy or a radiopharmaceutical'; the antitumor activity figures (≥50% PSA decline in 67% of 42, RECIST partial responses in 9/24, Abstract Results) therefore apply solely to the chemotherapy-naive population. The low-dose glucocorticoid component is supported in that the study prospectively added dexamethasone 0.5 mg/d at progression and reversed resistance in 33% of patients (Abstract Results; Discussion). What this source does not support is the post-chemotherapy arm of the claim: the Discussion mentions only that a phase III study of abiraterone plus prednisone in docetaxel-treated patients 'is now being evaluated,' with no results reported here. (LLM, conf=0.85)
- Supportedcites [16] matched to “Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids” (2010) source
In the body of this correspondence (section 'Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids'), the authors open by summarising the three multicenter phase I/II studies of abiraterone acetate in CRPC (chemotherapy-naive Ryan et al, and the post-docetaxel Reid et al and Danila et al studies listed in their References) and state that their prechemotherapy data 'confirmed the significant antitumor activity of abiraterone acetate' (radiologic regression, PSA and circulating tumour cell decreases), that the combination with low-dose corticosteroids (dexamethasone/prednisone) gave 'durable secondary tumor responses... in 25% of patients', and close by affirming 'the significant and durable antitumor activity and the satisfactory safety profile of abiraterone acetate at 1,000 mg daily'. Low-dose prednisone is explicitly named. This source is correspondence reporting/summarising those trials rather than a primary trial report, but it states every element attributed to it here. (LLM, conf=0.82)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy is a single phase I trial, and it confirms significant antitumor activity (PSA declines ≥30%/≥50% in 66%/57% of 21 patients, RECIST partial responses in 5 of 8) in chemotherapy-naive CRPC (Antitumor Activity section), with low-dose dexamethasone 0.5 mg/d added at progression reinducing sensitivity in 4 of 15 patients (Reversal of Resistance section). However, the post-chemotherapy arm and the phase II results are not reported here: the Discussion (B2 C1 C2) states only that these findings 'have led to the phase II evaluation... in both chemotherapy-naïve and docetaxel-treated patients... data from this evaluation will be reported soon,' and the Patients section explicitly excluded men previously treated with chemotherapy. Prednisone is not the glucocorticoid used in this paper (dexamethasone was), so the 'phase 1-2 trials... both chemotherapy-naive and post-chemotherapy' scope is not carried by this source. (LLM, conf=0.78)
- Supportedcites [18] matched to “Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer” (2010) source
Our copy covers every element of the summary sentence. The Abstract and Results describe this phase II trial of abiraterone acetate 1,000 mg daily with low-dose prednisone 5 mg twice daily in 58 men with progressive metastatic CRPC after docetaxel failure, reporting significant antitumor activity (confirmed ≥ 50% PSA decline in 36%, partial responses in 4/22 RECIST-evaluable patients, ECOG improvement in 28%). The Introduction states that 'Significant antitumor effects were seen in patients with progressive CRPC who had not received prior chemotherapy' (citing the phase I trial, Attard 2008, and the phase II chemo-naive AA-plus-prednisone study, Ryan 2009) and that 'In a separate trial, we showed significant antitumor effects of abiraterone acetate (AA) monotherapy in this patient group' (post-docetaxel, Reid/Danila), i.e. activity with AA alone as well as with low-dose steroid, in both chemotherapy-naive and post-chemotherapy settings. The Discussion likewise frames this as 'the second trial showing the activity of AA in patients ... who have progressed on chemotherapy.' (LLM, conf=0.85)
- Partly supportedcites [19] matched to “Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate” (2010) sourceExperimental — accuracy not yet measured
Our copy directly supports the trial/patient-population part: the Conclusion (p. 1) and DISCUSSION (p. 5) state that abiraterone acetate 1,000 mg had significant antitumor activity in post-docetaxel CRPC (≥50% PSA declines in 51%, with radiologic, symptomatic and CTC support), and the INTRODUCTION (p. 2) plus DISCUSSION (p. 6) report the authors' own phase I and phase II pre-docetaxel (chemotherapy-naïve) studies as showing abiraterone 'well tolerated and active'. What our copy does not support is the efficacy attribution to a glucocorticoid combination: low-dose glucocorticoids (and eplerenone) appear only as management of mineralocorticoid-excess toxicities (Treatment and Procedures, p. 3; Safety, p. 5; DISCUSSION, p. 6), the trial itself was single-agent abiraterone, and prednisone co-administration is mentioned only as the design of the subsequent phase III trial (DISCUSSION, p. 5), not as a phase 1-2 activity result. (LLM, conf=0.78)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) supports only part of the sentence: the DISCUSSION (p. 1) states 'Abiraterone acetate has significant activity in patients with CRPC, as evidenced by a PSA response rate of 58% in this phase I trial,' and RESULTS/Efficacy report confirmed ≥50% PSA declines in 55%-58% of men with chemotherapy-naïve progressive CRPC, including 47% of those with prior ketoconazole. However, this is a single-agent phase I dose-escalation trial only — 'Prior chemotherapy for prostate cancer was not allowed' (Major Eligibility Criteria), and the DISCUSSION states the exclusion of prior-chemotherapy patients was intentional, with 'ongoing studies...evaluating abiraterone in patients with both chemotherapy-refractory and chemotherapy-naïve CRPC,' so the post-chemotherapy activity attributed here is not from this paper. Glucocorticoids were also not part of the tested regimen: prednisone/corticosteroids were used reactively to manage mineralocorticoid toxicity, and the authors only 'suggest that a low dose of a corticosteroid, such as prednisone, be administered with abiraterone acetate in future studies'; the DISCUSSION notes 'the impact of concurrent prednisone on response proportion and durability...is not known.' (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile observed in the group of patients who received abiraterone acetate was similar to that observed in earlier clinical studies.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
Our copy details the safety profile of the 1,000-mg abiraterone acetate group in RESULTS > Safety Profile (secondary mineralocorticoid excess: hypokalemia 88%, hypertension 40%, fluid overload 31%, managed with eplerenone; grade 3 transaminase elevation in 2 patients; grade 1 headaches/joint aches) and calls it 'effective, well-tolerated' in the DISCUSSION, so the first half of the claim is grounded. However, no passage states that this profile was 'similar to that observed in earlier clinical studies'; the only cross-study safety remarks compare abiraterone with ketoconazole trials (grade >=3 toxicities in up to 30% of patients, all requiring hydrocortisone) and explicitly caution that 'it is difficult to make any comparisons.' The prior abiraterone phase I experience is referenced (ref 15) as having identified the 1,000-mg dose, not as a matched safety comparison. The comparative/similarity element is therefore unsupported by our copy. (LLM, conf=0.68)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy documents this trial's own safety profile (Safety and Tolerability: dose escalation to 2,000 mg achieved, no treatment-related grade 3 or 4 toxicities, hypertension/hypokalemia/edema controlled with eplerenone; DISCUSSION: toxicities predominantly due to secondary mineralocorticoid excess), and the INTRODUCTION notes that first-in-man studies reported abiraterone acetate was safe when given daily for 12 days to men with prostate cancer. However, no passage compares the two or states the profiles were similar; the only 'similar' statement in the paper is of hypertension incidence across dose levels within this study, and the DISCUSSION frames this as 'the first study to demonstrate that selective and continuous inhibition of CYP17 is safe', with the earlier clinical experience being short-course dosing in noncastrate men. The comparative element of the claim ('similar to that observed in earlier clinical studies') is therefore not supported by this source. (LLM, conf=0.65)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) describe their own safety findings as acceptable and consistent with expected CYP17 inhibition (DISCUSSION: 'The adverse event and steroid endocrine profiles were consistent with anticipated outcomes of selective CYP17 inhibition'; well tolerated through 1,000 mg/d with no MTD and no toxicity difference by prior ketoconazole exposure, DISCUSSION). However, the only external comparison our copy makes is to a CONCURRENT study, not to earlier clinical studies: RESULTS (Dose Escalation) states 'These findings paralleled a concurrent study with abiraterone acetate.' The claim's framing of similarity to 'earlier clinical studies' is therefore not supported by this source. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
23 more claims · 3 with their cited sources checked
Create a free account to see all 50 claims and to verify the 23 references still open.
- It may state two separate claims as one. 10
- The quote only partly states this claim. 3
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Abiraterone acetate is an orally active prodrug of abiraterone, a potent P450c17 inhibitor (316) indicated for treatment of castration-resistant prostate cancer (317, 318).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [317]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [20]
In the citing paper
“Abiraterone is a potent CYP17A1 inhibitor that efficiently inhibits testosterone production120 and is used to treat prostate cancer.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [120]
In the citing paper
“Additionally, androgen biosynthesis from C21 precursors can be reduced by CYP17A1 inhibition with abiraterone as successfully applied for the treatment of CRPC (Attard et al., 2008, de Bono et al., 2011, James et al., 2017).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as de Bono et al., 2011
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 3×
“Bone pain 194 (25) 42 (5) 2 (<1) 110 (28) 25 (6) 4 (1)”
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241 · cited 1×
“Fluid retention and edema 241 (31) 16 (2) 2 (<1) 88 (22) 4 (1) 0”
Self-citationde Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182 · cited 2×
“Nausea 233 (30) 12 (2) 1 (<1) 124 (32) 10 (3) 0”
Self-citationDevelopment of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562
Cited by
Items 701–800 of 1,010
Aly, M., Levál, A., Schain, F., Liwing, J., Lawson, J., Vágó, E., Nordström, T., Andersson, T., Sjöland, E., Wang, C., et al. (2020) · Scandinavian Journal of Urology · doi:10.1080/21681805.2020.1739139 · Cited by 69
Recent advances and future perspectives in the therapeutics of prostate cancer
Varaprasad, G. L., Gupta, V., Prasad, K., Kim, E., Tej, M. B., Mohanty, P., Verma, H. K., Raju, G. S. R., Bhaskar, L. V., & Huh, Y. S. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00444-9 · Cited by 80
Fred Saad, C., & Fizazi, K. S. (2015) · Urology · doi:10.1016/j.urology.2015.07.034 · Cited by 71
Self-citationA Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
Armstrong, A. J., Shen, T., Halabi, S., Kemeny, G., Bitting, R. L., Kartcheske, P. A., Embree, E., Morris, K. K., Winters, C., Jaffe, T. A., et al. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.05.007 · Cited by 69
Oh, S. J., Erb, H. H. H., Hobisch, A., Santer, F. R., & Čulig, Z. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0298 · Cited by 65
“On the basis of a recent publication by de Bono et al. (2011) that administration of the inhibitor of androgen synthesis abiraterone in combination with prednisone in patients pretreated with docetaxel prolonged survival to 450 vs 332 days, it could be concluded that targeting the androgen…”
BackgroundCho, Y., Chang, J. S., Rha, K. H., Hong, S. J., Choi, Y. D., Ham, W. S., Kim, J. W., & Cho, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147191 · Cited by 64
Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer
Zacharias, N. M., McCullough, C., Shanmugavelandy, S. S., Lee, J.-H., Lee, Y., Dutta, P., McHenry, J., Nguyen, L., Norton, W., Jones, L. W., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16327-z · Cited by 74
Pak, S., Park, S., Kim, Y., Park, J., Park, C. H., Lee, K.-J., Kim, C., & Ahn, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1342-5 · Cited by 66
The clinical and biochemical significance of 11-oxygenated androgens in human health and disease
Storbeck, K.-H., & O’Reilly, M. W. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad047 · Cited by 63
Saad, F., Shore, N., Van Poppel, H., Rathkopf, D. E., Smith, M. R., de Bono, J. S., Logothetis, C. J., de Souza, P., Fizazi, K., Mulders, P. F. A., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.032 · Cited by 63
Self-citationImplementing the FAIR Data Principles in precision oncology: review of supporting initiatives
Vesteghem, C., Brøndum, R. F., Sønderkær, M., Sommer, M., Schmitz, A., Bødker, J. S., Dybkær, K., El‐Galaly, T. C., & Bøgsted, M. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz044 · Cited by 70
Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Feng, F. Y.-C., Brenner, J. C., Hussain, M., & Chinnaiyan, A. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0275 · Cited by 76
Bertaglia, V., Tucci, M., Fiori, C., Aroasio, E., Poggio, M., Buttigliero, C., Grande, S., Saini, A., Porpiglia, F., & Berruti, A. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.01.002 · Cited by 63
Kumano, M., Furukawa, J., Shiota, M., Zardan, A., Zhang, F., Beraldi, E., Wiedmann, R. M., Fazli, L., Zoubeidi, A., & Gleave, M. E. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0072 · Cited by 68
“Although docetaxel chemotherapy (2) and,more recently, AR pathway inhibitors such as abiraterone (3) and MDV3100 prolong survival by several months, treatment resistance frequently emerges, highlighting the need for”
Schweizer, M. T., & Antonarakis, E. S. (2012) · Therapeutic Advances in Urology · doi:10.1177/1756287212452196 · Cited by 68
“Higher rates of mineralocorticoid-related adverse events such as fluid retention, hypertension and hypokalemia were reported in the abiraterone arm, although grade 3 and 4 events were rare [de Bono et al. 2011].”
BackgroundKluetz, P. G., Ning, Y. M., Maher, V. E., Zhang, L., Tang, S. W., Ghosh, D., Aziz, R. M., Palmby, T. R., Fletcher, E. P., Zirkelbach, J. F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2134 · Cited by 69
“9 months in the abiraterone acetate and placebo arms, respectively (11).”
BackgroundNew agents for prostate cancer
Agarwal, N., Lorenzo, G. D., Sonpavde, G., & Bellmunt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu038 · Cited by 71
Kim, T. J., & Koo, K. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155484 · Cited by 73
Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer
Cunningham, J. J., Thuijsman, F., Peeters, R., Viossat, Y., Brown, J. S., Gatenby, R. A., & Staňková, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243386 · Cited by 66
Application of support vector machine algorithm for early differential diagnosis of prostate cancer
Akinnuwesi, B. A., Olayanju, K. A., Aribisala, B. S., Fashoto, S. G., Mbunge, E., Okpeku, M., & Owate, P. (2022) · Data Science and Management · doi:10.1016/j.dsm.2022.10.001 · Cited by 70
van Soest, R. J., Nieuweboer, A. J. M., de Morrée, E. S., Chitu, D. A., Bergman, A. M., Goey, S. H., Bos, M. M. E. M., van der Meer, N., Hamberg, P., de Wit, R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.037 · Cited by 64
Chen, L., Mooso, B. A., Jathal, M. K., Madhav, A., Johnson, S. D., Spyk, E. N. V., Mikhailova, M., Ripoll, A. Z., Xue, L., Vinall, R. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1548 · Cited by 61
“9 months over controls (37) and it would be of interest to see whether this leads to an increase in ErbB3/HER2 as”
BackgroundThoms, J., Pra, A. D., Anborgh, P. H., Christensen, E. N., Fleshner, N. E., Ménard, C. M., Chadwick, K., Milosevic, M., Catton, C., Pintilie, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.345 · Cited by 62
“It will also be important to study OPN following second-generation AD therapies such as abiraterone or MDV3100 (de Bono et al, 2011; Scher et al, 2012).”
BackgroundAning, J. J., Wassersug, R. J., & Goldenberg, S. L. (2012) · Current Oncology · doi:10.3747/co.19.1287 · Cited by 72
Zumsteg, Z. S., & Zeléfsky, M. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70084-0 · Cited by 70
Couck, M., van Brummelen, D., Schallier, D. C. C., Grève, J. D., & Gidron, Y. (2013) · Oncology Reports · doi:10.3892/or.2013.2725 · Cited by 67
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
Kroon, J., Puhr, M., Buijs, J. T., van der Horst, G., Hemmer, D. M., Marijt, K. A., Hwang, M., Masood, M., Grimm, S., Storm, G., et al. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0343 · Cited by 62
Ojo, D., Lin, X., Wong, N., Gu, Y. J., & Tang, D. (2015) · Cancers · doi:10.3390/cancers7040890 · Cited by 68
“Both inhibitors conferred survival advantages in men with taxane-resistant CRPC for 4–5 months [11,12].”
BackgroundInfluentialAR-V7 and prostate cancer: The watershed for treatment selection?
Ciccarese, C., Santoni, M., Brunelli, M., Buti, S., Modena, A., Nabissi, M., Artibani, W., Martignoni, G., Montironi, R., Tortora, G., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.12.003 · Cited by 68
Maines, F., Caffo, O., Veccia, A., Trentin, C., Tortora, G., Galligioni, E., & Bria, E. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.07.013 · Cited by 69
Abiraterone in Metastatic Prostate Cancer.
James, N. D., Spears, M. R., & Sydes, M. R. (2017) · PubMed · doi:10.1056/nejmc1711029 · Cited by 16
Kulkarni, H., Singh, A., Langbein, T., Schuchardt, C., Müeller, D., Zhang, J., Lehmann, C., & Baum, R. P. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180308 · Cited by 66
Torquato, S., Pallavajjala, A., Goldstein, A., Toro, P. V., Silberstein, J. L., Lee, J., Nakazawa, M., Waters, I. G., Chu, D. T. W., Shinn, D., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00227 · Cited by 67
“…target the androgen-androgen receptor (AR) axis, such as abiraterone and enzalutamide, have improved survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC), 1–4 but both primary and acquired resistance to these drugs continue to be a substantial clinical challenge.”
Rosar, F., Krause, J., Bartholomä, M. D., Maus, S., Stemler, T., Hierlmeier, I., Linxweiler, J., Ezziddin, S., & Khreish, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050722 · Cited by 62
“In the stage of mCRPC, taxane-based chemotherapy (docetaxel and cabazitaxel) [6,7], treatment with novel androgen axis drugs (NAAD) (abiraterone or enzalutamide) [8,9] and bone-seeking 223Ra therapy (Xofigo®) [10] are currently the standard treatment options [11], which are approved by the European Medicines Agency (E…”
BackgroundAndrogen pathway resistance in prostate cancer and therapeutic implications
Maughan, B. L., & Antonarakis, E. S. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1055249 · Cited by 65
“Both these agents have been tested in men with metastatic CRPC both pre-chemotherapy [17,18] and post-chemotherapy [19,20] with improvements in overall survival observed compared to placebo in large, Phase III clinical trials.”
BackgroundTamae, D., Mostaghel, E., Montgomery, B., Nelson, P. S., Balk, S. P., Kantoff, P. W., Taplin, M.-E., & Penning, T. M. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.12.012 · Cited by 61
“The P450c17 inhibitor, AA, has been shown to extend median survival in CRPC patients [31, 32].”
BackgroundMolecular Pathways: Targeting Resistance in the Androgen Receptor for Therapeutic Benefit
Mostaghel, E. A., Plymate, S. R., & Montgomery, B. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3601 · Cited by 69
Galletti, G., Portella, L., Tagawa, S. T., Kirby, B. J., Giannakakou, P., & Nanus, D. M. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0101-8 · Cited by 68
Abiraterone in Prostate Cancer: A New Angle to an Old Problem
Stein, M. N., Goodin, S., & DiPaola, R. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1805 · Cited by 61
Acharya, M. R., Gonzalez, M., Mannens, G., Vries, R. D., Lopez, C., Griffin, T., & Tran, N. (2012) · Xenobiotica · doi:10.3109/00498254.2012.721022 · Cited by 65
Flaig, T. W., Potluri, R. C., Ng, Y., Todd, M. B., & Mehra, M. (2015) · Cancer Medicine · doi:10.1002/cam4.576 · Cited by 65
“Cabazitaxel June 2010 No Yes Next generation taxane Tropic [13] Abiraterone acetate April 20115 December 20125 Yes Yes Androgen synthesis inhibitor COUAA301 [19, 27] COUAA302 [28] Enzalutamide August 20126 September 20146 Yes Yes Androgen receptor antagonist AFFIRM [20] PREVAIL [29] Radium223 May 2013 CRPC unfit or de…”
BackgroundSelf-citationPérez-López, R., Lorente, D., Blackledge, M., Collins, D. J., Mateo, J., Bianchini, D., Omlin, A. G., Zivi, A., Leach, M. O., Bono, J. S. D., et al. (2016) · Radiology · doi:10.1148/radiol.2015150799 · Cited by 61
Self-citationGaleterone for the treatment of advanced prostate cancer: the evidence to date
Antonarakis, E. S., & Bastos, D. A. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s93941 · Cited by 66
Lohiya, V., Aragon-Ching, J. B., & Sonpavde, G. (2016) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s34535 · Cited by 60
DNA vaccines for prostate cancer
Zahm, C. D., Colluru, V. T., & McNeel, D. G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.016 · Cited by 64
“, 2004), androgen receptor targeted agents abiraterone and enzalutamide (Bono et al., 2011; Scher et al., 2012), bone-targeted radiation therapy with radium-223 (Parker et al.”
BackgroundRice, M. A., Hsu, E., Aslan, M., Ghoochani, A., Su, A., & Stoyanova, T. I. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0804 · Cited by 63
“org Mol Cancer Ther; 18(7) July 2019 1231”
InfluentialAnti-androgen hormonal therapy for cancer and other diseases
Student, S., Hejmo, T., Poterała-Hejmo, A., Leśniak, A., & Bułdak, R. J. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172783 · Cited by 68
Disparities in prostate cancer incidence and mortality rates: Solvable or not?
Badal, S. A. M., Aiken, W. D., Morrison, B. F., Valentine, H., Bryan, S., Gachii, A., & Ragin, C. C. R. (2019) · The Prostate · doi:10.1002/pros.23923 · Cited by 74
“that blocks cytochrome p450 c17 (CYP 17) also increases survival in men with metastatic PCa and may be used in these patients with or without prior exposure to docetaxel chemotherapy.(165) Apalutamide is a competitive inhibitor of the androgen receptor and may be used in non‐metastatic and metastatic CRPC.”
Qi, J., Yang, Z., Lin, T., Ma, L., Wang, Y., Zhang, Y., Gao, C.-C., Liu, K.-L., Li, W., Zhao, A., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01814-5 · Cited by 67
“Currently, several compounds, including abiraterone acetate [5], enzalutamide [6], sipuleucel-T [7], alpharadin [8], and docetaxel [9] have been used to help treat PCa.”
BackgroundWorkman, P., Al‐Lazikani, B., & Clarke, P. A. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.06.004 · Cited by 65
Pathmanandavel, S., Crumbaker, M., Yam, A. O. W., Nguyen, A., Rofe, C., Hovey, E. J., Gedye, C. A., Kwan, E. M., Hauser, C., Azad, A., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262552 · Cited by 64
“Pain palliation was defined as a reduction by at least 30% in the worst pain intensity score over the last 24 h observed at 2 consecutive evaluations (20).”
MethodSadrkhanloo, M., Paskeh, M. D. A., Hashemi, M., Raesi, R., Motahhary, M., Saghari, S., Sharifi, L., Bokaie, S., Mirzaei, S., Entezari, M., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114168 · Cited by 66
Salvador, J. A. R., Pinto, R. M. A., & Silvestre, S. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.04.006 · Cited by 82
An update on enzalutamide in the treatment of prostate cancer
Merseburger, A. S., Haas, G. P., & von Klot, C. A. (2014) · Therapeutic Advances in Urology · doi:10.1177/1756287214555336 · Cited by 67
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies
Santoni, M., Guerra, F., Conti, A., Lucarelli, A., Rinaldi, S., Belvederesi, L., Capucci, A., & Berardi, R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.006 · Cited by 62
“…Age (Control arm) Male/Female (Target therapy) Male/Female (Control arm) Follow-up duration (months) Jadad Ref Target therapy Control arm de Bono et al. 2011 3 Prostate Cancer Abiraterone acetate Prednisone 791 394 69 69 100/0 100/0 12.8 4 38 Ryan et al. 2013 3 Prostate Cancer Abiraterone…”
InfluentialRathkopf, D. E., Beer, T. M., Loriot, Y., Higano, C. S., Armstrong, A. J., Sternberg, C. N., Bono, J. S. D., TOMBAL, B. F., Parli, T., Bhattacharya, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5808 · Cited by 67
Self-citationRe, M. D., Conteduca, V., Crucitta, S., Gurioli, G., Casadei, C., Restante, G., Schepisi, G., Lolli, C., Cucchiara, F., Danesi, R., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-00309-w · Cited by 63
Ryan, C. J., Crawford, E. D., Shore, N. D., Underwood, W., Taplin, M., Londhe, A., Francis, P. S. J., Phillips, J., McGowan, T., & Kantoff, P. W. (2018) · The Journal of Urology · doi:10.1016/j.juro.2018.03.125 · Cited by 61
“radiographic progression patients should remain on therapy, as in the phase 3 studies of AAþP.(3,15) 3) There was no overall survival end point.”
BackgroundSelf-citationPlectin is a regulator of prostate cancer growth and metastasis
Buckup, M., Rice, M. A., Hsu, E.-C., Garcia-Marques, F., Liu, S., Aslan, M., Bermudez, A., Huang, J., Pitteri, S. J., & Stoyanova, T. (2021) · Oncogene · doi:10.1038/s41388-020-01557-9 · Cited by 59
“Bone is the most common site of distant metastasis, followed by lung, lymph node, and liver, the most lethal metastatic site [2, 6].”
BackgroundMAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT
Shen, T., Wang, W., Zhou, W., Coleman, I. M., Cai, Q., Dong, B., Ittmann, M., Creighton, C. J., Bian, Y., Meng, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135465 · Cited by 61
A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
Crowley, F., Sterpi, M., Buckley, C. W., Margetich, L., Handa, S., & Dovey, Z. (2021) · Research and Reports in Urology · doi:10.2147/rru.s264722 · Cited by 73
Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer
Yamada, Y., Venkadakrishnan, V. B., Mizuno, K., Bakht, M. K., Ku, S., Garcia, M. M., & Beltran, H. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf6732 · Cited by 68
Constitutive Activity of the Androgen Receptor
Chan, S. C., & Dehm, S. M. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-417197-8.00011-0 · Cited by 71
“Clinical trials have demonstrated that abiraterone acetate prolongs overall survival in CRPC patients that have received prior taxane chemotherapy (de Bono et al., 2011), as well as chemotherapy-naïve patients (Ryan et al., 2013).”
BackgroundNing, Y. M., Pierce, W. F., Maher, V. E., Karuri, S. W., Tang, S. W., Chiu, H.-J., Palmby, T. R., Zirkelbach, J. F., Marathe, D. D., Mehrotra, N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1763 · Cited by 65
Bono, J. S. D., Molife, L. R., Sonpavde, G., Maroto, P., Calvo, E., Cartwright, T. H., Loesch, D. M., Feit, K., Das, A., Zang, E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr380 · Cited by 60
“Indeed, abiraterone acetate was recently reported to significantly extend survival in men with progressive metastatic CRPC following prior docetaxel treatment, leading to regulatory approval [23].”
BackgroundMolecular landscape of prostate cancer: Implications for current clinical trials
Khemlina, G., Ikeda, S., & Kurzrock, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.07.001 · Cited by 65
“Although abiraterone and enzalutamide showed survival benefit in castrate-resistant disease, prostate cancer cells eventually develop resistance [13–15].”
BackgroundInfluentialCopy number variations in urine cell free DNA as biomarkers in advanced prostate cancer
Xia, Y. F., Huang, C., Dittmar, R. L., Du, M., Wang, Y., Liu, H., Shenoy, N. K., Wang, L., & Kohli, M. (2016) · Oncotarget · doi:10.18632/oncotarget.9027 · Cited by 62
“Despite this advance, emergence of castration-resistant prostate cancer (CRPC) is inevitable and is treated with systemic chemotherapy with docetaxel [3-7] and several novel systemic anti-cancer therapies [8-17].”
BackgroundFan, L., Wang, R., Chi, C., Cai, W., Zhang, Y., Qian, H., Shao, X., Wang, Y., Xu, F., Pan, J., et al. (2017) · The Prostate · doi:10.1002/pros.23465 · Cited by 67
Wargowski, E., Johnson, L. E., Eickhoff, J. C., Delmastro, L., Staab, M. J., Liu, G., & McNeel, D. G. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0333-y · Cited by 59
“including docetaxel [2, 3], cabazitaxel [4], abiraterone [5], radium-223 [6], and enzalutamide [7].”
BackgroundAttard, G., Merseburger, A. S., Arlt, W., Sternberg, C. N., Feyerabend, S., Berruti, A., Joniau, S., Géczi, L., Lefresne, F., Lahaye, M., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1011 · Cited by 64
Self-citationNaiki‐Ito, A., Naiki, T., Kato, H., Iida, K., Etani, T., Nagayasu, Y., Suzuki, S., Yamashita, Y., Inaguma, S., Onishi, M., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz193 · Cited by 59
“Although enzalutamide and abiraterone have been approved for CRPC hormone therapy (16,17), and several new drugs are under development, including EPI-002 and galeterone (18,19), the efficacy of these drugs is limited.”
BackgroundEZH2-mediated development of therapeutic resistance in cancer
Kaur, P., Shankar, E., & Gupta, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216706 · Cited by 71
Schaefer-Schuler, A., Burgard, C., Blickle, A., Maus, S., Petrescu, C., Petto, S., Bartholomä, M. D., Stemler, T., Ezziddin, S., & Rosar, F. (2024) · Theranostics · doi:10.7150/thno.92273 · Cited by 66
“Common treatments for mCRPC patients include new androgen axis drugs as abiraterone or enzalutamide [4,5], chemotherapy with docetaxel or cabazitaxel [6,7], bone seeking radiation therapy with Ra-223 [8], and PARP inhibitors as e.g. Olaparib [9].”
Hoy, S. M. (2013) · Drugs · doi:10.1007/s40265-013-0150-z · Cited by 65
“Table 3 Key design details of a multinational phase III study investigating the efficacy of oral abiraterone acetate plus oral prednisone in men with metastatic castration-resistant prostate cancer who had previously received docetaxel [25, 26]”
BackgroundMethodInfluentialHighly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors
Rafferty, S. W., Eisner, J. R., Moore, W. R., Schotzinger, R. J., & Hoekstra, W. J. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.04.024 · Cited by 60
New and emerging agents for the treatment of castration-resistant prostate cancer
Higano, C. S., & Crawford, E. D. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.08.013 · Cited by 64
Gillis, J. L., Selth, L. A., Centenera, M. M., Townley, S. L., Sun, S., Plymate, S. R., Tilley, W. D., & Butler, L. M. (2013) · Oncotarget · doi:10.18632/oncotarget.975 · Cited by 61
“While abiraterone and enzalutamide have improved the clinical outlook of men with CRPC, they are not curative [20, 21].”
BackgroundAR-v7 protein expression is regulated by protein kinase and phosphatase
Li, Y., Xie, N., Gleave, M. E., Rennie, P. S., & Dong, X. (2015) · Oncotarget · doi:10.18632/oncotarget.5608 · Cited by 61
“While the new generation of antiandrogens such as enzalutamide (ENZ) targets the ligand binding domain (LBD) of the AR and blocks AR activity efficiently, resistance to ENZ develops in essentially all patients [4, 5].”
BackgroundRetractedCYP17 inhibitors in prostate cancer: latest evidence and clinical potential
Alex, A. B., Pal, S. K., & Agarwal, N. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016642370 · Cited by 67
Emerging data on androgen receptor splice variants in prostate cancer
Cao, S., Zhan, Y., & Dong, Y. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0298 · Cited by 66
Terada, N., Maughan, B. L., Akamatsu, S., Kobayashi, T., Yamasaki, T., Inoue, T., Kamba, T., Ogawa, O., & Antonarakis, E. S. (2017) · International Journal of Urology · doi:10.1111/iju.13346 · Cited by 58
The expression of AURKA is androgen regulated in castration-resistant prostate cancer
Kivinummi, K. K., Urbanucci, A., Leinonen, K. A., Tammela, T. L. J., Annala, M., Isaacs, W. B., Bova, G. S., Nykter, M., & Visakorpi, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-18210-3 · Cited by 59
Liang, C., Wang, S., Qin, C., Bao, M., Cheng, G., Liu, B., Shao, P., Lv, Q., Song, N., Hua, L., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0197-y · Cited by 59
Prostate Cancer in the Elderly Patient
Fung, C., Dale, W., & Mohile, S. G. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1531 · Cited by 62
McKay, R. R., Feng, F. Y.-C., Wang, A. Y., Wallis, C. J. D., & Moses, K. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279459 · Cited by 62
Global experience with PSMA-based alpha therapy in prostate cancer
Sathekge, M. M., Bruchertseifer, F., Vorster, M., Morgenstern, A., & Lawal, I. O. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05434-9 · Cited by 64
Rosar, F., Kochems, N., Bartholomä, M. D., Maus, S., Stemler, T., Linxweiler, J., Khreish, F., & Ezziddin, S. (2021) · Cancers · doi:10.3390/cancers13123095 · Cited by 67
“Besides established chemotherapy with taxanes (docetaxel, cabazitaxel) [1–3] and treatment with novel androgen axis drugs (NAAD) (abiraterone or enzalutamide) [4,5], radioligand therapy targeting the prostate-specific membrane antigen (PSMA) is a promising therapy option in metastatic castration-resistant prostate car…”
BackgroundXiang, Q., Wang, C., Wu, T., Zhang, C., Hu, Q., Luo, G., Hu, J., Zhuang, X., Zou, L., Shen, H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01864 · Cited by 59
ST6GAL1 ‐mediated aberrant sialylation promotes prostate cancer progression
Scott, E., Goode, E. A., Garnham, R., Hodgson, K., Orozco‐Moreno, M., Turner, H., Livermore, K. E., Nangkana, K. P., Frame, F. M., Bermudez, A., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6152 · Cited by 65
“Numerous second-generation ADT treatments, such as abiraterone [3,4], enzalutamide [5,6], and, more recently, darolutamide [7], are available for CRPC; however, nearly all patients will also develop resistance to these treatments [8].”
BackgroundTargeting the interleukin‐11 receptor α in metastatic prostate cancer: A first‐in‐man study
Pasqualini, R., Millikan, R. E., Christianson, D. R., Cardó‐Vila, M., Driessen, W. H. P., Giordano, R. J., Hajitou, A., Hoang, A. G., Wen, S., Barnhart, K. F., et al. (2015) · Cancer · doi:10.1002/cncr.29344 · Cited by 58
Self-citationCastration‐resistant prostate cancer: Many treatments, many options, many challenges ahead
Garcia, J. A., & Rini, B. I. (2011) · Cancer · doi:10.1002/cncr.26582 · Cited by 62
“Overall survival in the COU-AA-301 trial.(90) Castration-Resistant Prostate Cancer/Garcia and Rini”
MethodFactors affecting 223Ra therapy: clinical experience after 532 cycles from a single institution
Etchebehere, E., Milton, D. R., Araujo, J. C., Swanston, N. M., Macapinlac, H. A., & ROHREN, E. M. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3185-4 · Cited by 57
“2 months) [10–12].”
Conteduca, V., Burgio, S. L., Menna, C., Carretta, E., Rossi, L., Bianchi, E., Masini, C., Amadori, D., & Giorgi, U. D. (2014) · The Prostate · doi:10.1002/pros.22890 · Cited by 57
“The lack of correlation between baseline serum CgA levels and PSA response coupled with the prognostic role of CgA in patients treated with enzalutamide and even abiraterone, as reported in a previous study [15], confirm that serum CgA levels could be the expression of a subclone of prostate cancer cells with NED resp…”
BackgroundResultGuan, M., Su, L., Yuan, Y., Li, H., & Chow, W. A. (2015) · Scientific Reports · doi:10.1038/srep09698 · Cited by 61
Bourke, L., Kirkbride, P., Hooper, R., Rosario, A. J., Chico, T., & Rosario, D. J. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.523 · Cited by 60
“This is particularly relevant given the recent introduction of the novel androgen synthesis inhibitor, abiraterone (de Bono et al, 2011) and reported similar improved survival results for enzalutamide, a first-in-class androgen inhibitor (Scher et al, 2012) in men with chemotherapy relapsed…”
BackgroundDamiano, J. S., & Wasserman, E. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0138 · Cited by 59
Montgomery, B., Kheoh, T. S., Molina, A., Li, J., Joaquim Bellmunt, B., Tran, N., Loriot, Y., Efstathiou, E., Ryan, C. J., Scher, H. I., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.06.042 · Cited by 59
“docetaxel [11,18].”
BackgroundInfluentialSelf-citationRoviello, G., Sigala, S., Sandhu, S. K., Bonetta, A., Cappelletti, M. R., Zanotti, L., Bottini, A., Sternberg, C. N., Fox, S. B., & Generali, D. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.002 · Cited by 59
Self-citationSato, S., Katsushima, K., Shinjo, K., Hatanaka, A., Ohka, F., Suzuki, S., Naiki‐Ito, A., Soga, N., Takahashi, S., & Kondo, Y. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3339 · Cited by 62
The Molecular Evolution of Castration-resistant Prostate Cancer
Ceder, Y., Bjartell, A. S., Čulig, Z., Rubin, M. A., Tomlins, S. A., & Visakorpi, T. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.11.012 · Cited by 62
Metadata
- Authors
- de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., Patterson, H., Hainsworth, J. D., Ryan, C. J., Sternberg, C. N., Ellard, S. L., Fléchon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C. M., & Scher, H. I.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Institut Gustave Roussy (FR)
- Cross Cancer Institute (CA)
- BC Cancer Agency (CA)
- University of Glasgow (GB)
- Institute of Cancer Research (GB)
- Velindre Cancer Centre (GB)
- University College London (GB)
- University of Colorado Cancer Center (US)
- University of Calgary (CA)
- University of California, San Francisco (US)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- Centre Léon Bérard (FR)
- Georgia Cancer Specialists (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Logothetis, Christopher J.
- Molina, Arturo
- Fizazi, Karim
- North, Scott
- Chi, Kim N.
- Jones, Robert J.
- Goodman, Oscar B.
- Staffurth, John N.
- Mainwaring, Paul
- Flaig, Thomas W.
- Hutson, Thomas E.
- Cheng, Tina
- Hainsworth, John D.
- Ryan, Charles J.
- Sternberg, Cora N.
- Ellard, Susan L.
- Fléchon, Aude
- Saleh, Mansoor
- Efstathiou, Eleni
- Bianchini, Diletta
- Loriot, Yohann
- Kheoh, Thian
- Haqq, Christopher M.
- Scher, Howard I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-26
- Volume
- 364
- Issue
- 21
- Pages
- 1995-2005
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3471149
- OpenAlex
- W2110534364
- Cited by
- 4,407
- References
- 54
- Citations by year
- 2026: 111 · 2025: 184 · 2024: 187 · 2023: 209 · 2022: 235 · 2021: 287 · 2020: 290 · 2019: 299 · 2018: 332 · 2017: 322 · 2016: 342 · 2015: 352 · 2014: 384 · 2013: 403 · 2012: 347
- FWCI
- 336.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Prostate Cancer Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Exelixis
- Les Laboratories Pierre Fabre
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research
- Astellas Pharma
- Genentech
- Foundation Medicine
- Medical Research Council
- National Cancer Institute (P50CA092629)
- Cilag
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- abiraterone, metastatic castration-resistant prostate cancer, androgen biosynthesis inhibition, overall survival, docetaxel, prednisone, prostate-specific antigen progression, progression-free survival, fluid retention, hypokalemia, hypertension
- MeSH terms
- Aged, Androgen Antagonists, Androgens, Androstenes, Androstenols, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Fatigue, Humans, Male, Middle Aged, Neoplasm Metastasis, Prednisone, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Survival Analysis, Treatment Outcome, Disease Progression, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.